Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06968390 · ClinicalTrials.gov registry record · NA

Accelerated TMS for Perinatal Depression

A NA study of Major Depressive Disorder and Postpartum Depression, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT06968390: Recruiting NA study of Major Depressive Disorder and Postpartum Depression, sponsored by Brigham and Women's Hospital.

NCT06968390 is a NA study of Major Depressive Disorder and Postpartum Depression that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 24 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06968390, a NA study of Major Depressive Disorder and Postpartum Depression, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

We are studying a treatment for depression called accelerated Transcranial Magnetic Stimulation (TMS) among pregnant and postpartum individuals. TMS is a focal, non-invasive form of brain stimulation that is cleared by the Food and Drug Administration for depression. Typically, traditional TMS involves daily treatments for 6-8 weeks. In this study, we will offer an accelerated form of TMS that involves multiple daily treatments for 5 days.

Primary Outcome

The CSQ-8 asks individuals about their overall experience with aTMS.Higher scores indicate a greater level of tolerability. We hypothesize that participants will report high levels of treatment satisfaction (\>24) on the Client Satisfaction Questionnaire (CSQ-8). The primary outcome will be a composite defined as meeting 3 out of 4 metrics listed here.

Interventions

  • DEVICE Transcranial Magnetic Stimulation

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-08-05
Est. Completion 2027-01-01
Phase NA
Brigham and Women's Hospital

937 total trials

What NCT06968390 shows while recruiting

NCT06968390 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (94% lower).

The record links to 3 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Transcranial Magnetic Stimulation is the first listed.

NCT06968390 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06968390 about?

NCT06968390 is a clinical study titled "Accelerated TMS for Perinatal Depression". We are studying a treatment for depression called accelerated Transcranial Magnetic Stimulation (TMS) among pregnant and postpartum individuals. TMS is a focal, non-invasive form of brain stimulation that is cleared by the Food and Drug Administration for depression. Typically, traditional TMS invol...

What is the current status of trial NCT06968390?

This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2025-08-05. Estimated completion is 2027-01-01.

What conditions does trial NCT06968390 study?

This clinical trial studies the following conditions: Major Depressive Disorder, Postpartum Depression, Perinatal Depression.

What interventions are being tested in trial NCT06968390?

The interventions under investigation include: Transcranial Magnetic Stimulation (DEVICE).

Who is sponsoring clinical trial NCT06968390?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06968390 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06968390's enrollment target sits among peer trials

24 236th of 282 higher than 45 of 282 other Major Depressive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06968390, the US trial registry maintained by the National Library of Medicine. NCT06968390 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.